Wisconsin is currently home to 1262 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286
Recruiting
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL). This study will be made up of two parts (Part 1 not randomized, Part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Prohealth Care Inc, Waukesha, Wisconsin
Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL)
Register for Updates
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748
Recruiting
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Aurora BayCare Medical Center, Green Bay, Wisconsin
Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967
Recruiting
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective risankizumab subcutaneous (SC) induction treatment is in treating moderately to severely active CD in adult participants. Risankizumab is an approved drug for adults with CD. This study comprises... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Wisconsin Center for Advanced Research /ID# 256575, Milwaukee, Wisconsin
Conditions: Crohn's Disease
Register for Updates
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689
Recruiting
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: IDS Pharmacy, Milwaukee, Wisconsin
Conditions: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Register for Updates
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/30/2025
Locations: Advocate Aurora Research institute, St. Luke's Medical Center, Milwaukee, Wisconsin
Conditions: Primary Generalized Tonic-Clonic Seizures
Register for Updates
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795
Recruiting
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.
Gender:
ALL
Ages:
25 years and below
Trial Updated:
05/30/2025
Locations: University of Wisconsin - Madison, Madison, Wisconsin
Conditions: Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Register for Updates
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NCT05503264
Recruiting
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/30/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Register for Updates
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
NCT05231629
Recruiting
This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow. For patients who become MRD "negative" (i.e. less than 1 cancer cell out of 100,000) at the end of 6 cycles of therapy, this study will study if that good response can be maintained with 3 additional cycles of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: University of Wisconsin - Carbone, Madison, Wisconsin
Conditions: Multiple Myeloma
Register for Updates
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755
Recruiting
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/30/2025
Locations: Aurora Saint Lukes Medical Center, Milwaukee, Wisconsin
Conditions: Moderate Aortic Valve Stenosis
Register for Updates
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
NCT05109975
Recruiting
This study has two parts: Part 1 and Part 2. The purpose of this study in Part 1, Dose Escalation Part is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of Debio 0123 as monotherapy with repeated dosing in adults with advanced solid tumors that recurred or progressed after prior therapy and/or for whom no standard therapy of proven benefit is available. The purpose in Part 2, Expansion Part of this study, is to characterize the safety and tolerability o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Advanced Solid Tumors
Register for Updates
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283
Recruiting
This is a study evaluating the safety, pharmacokinetics, and efficacy of MK-1084 alone, and MK-1084 plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: MEDICAL COLLEGE OF WISCONSIN-Cancer Center Clinical Trials Office ( Site 0262), Milwaukee, Wisconsin
Conditions: Advanced Solid Tumors
Register for Updates
TTVR Early Feasibility Study
NCT04433065
Recruiting
The objective of this early feasibility study is to gain early clinical insight into the performance of the Intrepid transcatheter tricuspid valve replacement (TTVR) system intended for transfemoral access to deliver a self-expanding bioprosthetic valve within the tricuspid valve.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Aurora St. Lukes Medical Center, Milwaukee, Wisconsin
Conditions: Tricuspid Regurgitation
Register for Updates